What we won't sell you, and why

Patients ask us for BPC-157 by name. They ask for the Wolverine stack. They send us screenshots of a vial that costs less than lunch and want to know if we’ll write for it.

The answer is no, and we’d rather explain why than just say it.

First, what we actually are

Dynamic Health Institute prescribes and fulfills. We don’t compound. Every product we offer is either an FDA-approved drug dispensed as approved, or a compounded preparation made by a licensed pharmacy or a registered outsourcing facility working under a lawful pathway for that specific substance.

That last clause does a lot of work. Federal law is narrow about what a pharmacy may compound from raw ingredient, and the list of what’s permitted is shorter than the internet suggests. When a pharmacy can’t lawfully make something, we can’t lawfully sell it. There’s no version of us that wants it badly enough to route around that.

The list

We don’t supply these, in any form, by any route, alone or blended:

• BPC-157, including anything sold as Pentadeca Arginate or PDA
• TB-500
• CJC-1295
• Ipamorelin
• Ibutamoren, sold as MK-677
• Melanotan II
• KPV, MOTS-c, Semax, Epitalon, Selank, DSIP, LL-37, Dihexa, PEG-MGF

And nothing marketed as a Wolverine, GLOW, or KLOW stack, which are just the above in combination.

We’re not saying these substances are junk. Several are under active FDA review right now, and some have real preclinical literature behind them. We’re saying no licensed pharmacy in the United States can currently fill them for us, which makes the question of whether they work academic. If that changes, we’ll look at the evidence and we’ll update this page.

Now the part that isn’t about us

You can buy every substance on that list this afternoon. That’s the problem worth understanding, and it has nothing to do with where you buy your care.

We won’t comment on any specific seller. We will describe how the category is built, because it determines what ends up in the vial.

“Research use only” is a shipping label. Products sold as research grade, or stamped “not for human consumption,” sit outside the rules that govern prescription drugs and pharmacy compounding. That phrase is what makes the sale legal for the seller. It says nothing about what’s inside. Everyone involved understands the arrangement. One reporter covering the market described the framing as a wink: sellers know the buyers aren’t running experiments.

A certificate of analysis is not release testing. A COA is one sample, one set of assays, usually commissioned by the party selling you the product. Pharmaceutical release testing is a different thing entirely: sterility assurance, potency across a lot, documented chain of custody, and a facility that answers to an inspector. A PDF is not that.

The name on the vial is a claim, not a fact. Salt forms, sequence variants, and relabeled compounds circulate under identical marketing names. This is not hypothetical: published case reports document patients who received a completely different drug than the one on the label, including one 2026 report of a metabolic emergency in a patient using counterfeit semaglutide.

The stack names came from social media, not medicine. “Wolverine” is named after the Marvel character. The term scaled through TikTok, where the peptide hashtag has been used on more than 270,000 videos. GLOW and KLOW are acronyms assembled from ingredient lists and sold pre-blended in a single vial. The combinations they describe have never been studied together in humans.

Watch for the tell. A remarkable number of pages explaining these compounds are written by companies selling them, complete with affiliate discount codes. Many present reconstitution math and syringe units on the same page as a disclaimer that the product isn’t for human use. When a seller gives you injection instructions and a note saying not to inject it, they have told you which of the two they mean.

And the regulatory news is being reported badly. You have probably seen that peptides “became legal again” in 2026. Federal action did not match the headline. Moving a substance out of a restricted category is not the same as authorizing anyone to compound it; it means the substance is waiting in line for evaluation. As of this page’s date, nothing on our list above became lawfully available because of any 2026 announcement. The advisory committee reviewing several of them has not finished, and even a favorable vote starts a rulemaking process measured in months.

Two questions worth asking anyone

If a clinician offers you something on our list, we’re not going to tell you how that conversation should end. But there are two questions with documentable answers:

1. Which pharmacy is filling this, under section 503A or 503B?
2. What is that pharmacy’s lawful basis for using this substance?

Any provider operating correctly can answer both in a sentence. If the answer is a brand name, a vibe, or a change of subject, you’ve learned what you needed to.

Why this page has a date on it

Status in this area moves, sometimes several times a year, and often without any public announcement: the underlying federal documents get quietly revised. We re-check this page on a schedule and after any FDA action touching the substances above. The date at the top is the last review. If you’re reading this long after it, go to the FDA’s bulk drug substances pages directly and trust those over us.

General information about our practice and about how these products are regulated. Not medical advice, and not a statement about the safety or effectiveness of any substance.